Loading
Micrornas / Alcoholic Liver Disease (ald) / Liver Diseases, Alcoholic · Journal article
Biomaterials · July 27, 2026
Raises a question worth testing. It does not answer one.
This is a bench-to-bedside hypothesis-generation study that identifies AKR1B10 as a transcriptomically dysregulated gene in a small ALD patient cohort, discovers four putative inhibitors by virtual screening, synthesizes novel covalent organic framework composites incorporating these molecules, and demonstrates that an ellagic acid-based variant reduces markers of liver injury in acutely alcohol-intoxicated mice. The work is mechanistically interesting but preclinical; no human efficacy, safety, or dose-finding data are presented, and no comparative efficacy against existing ALD therapies is established.
Transcriptomic observational cohort analysis combined with virtual screening, chemical synthesis, and uncontrolled preclinical animal efficacy testing. Transcriptomic cohort: 33 patients with alcoholic liver disease and 23 healthy controls (setting and eligibility criteria not stated). Animal efficacy cohort: acutely alcohol-intoxicated mice (strain, age, sex, and group sizes not specified).. Intervention: Bioactive molecule-derived covalent organic frameworks (COFs), specifically HA-grafted, zinc-coordinated COF composites incorporating ellagic acid, vitamin B8, hematoxylin, or porphyrin; ellagic acid-based COF system also loaded with miRNA….
AKR1B10 identified as dysregulated in transcriptomic analysis of 33 ALD patients versus 23 healthy controls Four inhibitors discovered via virtual screening: ellagic acid, vitamin B8, hematoxylin, and porphyrin Ellagic acid-based COF system ameliorated hepatocyte apoptosis, oxidative stress, lipid accumulation, and macrophage polarization in ALD mice
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work does not yet support clinical decision-making or patient treatment. It provides a foundation for drug discovery targeting AKR1B10 in ALD and highlights a novel COF-based delivery platform, but requires progression through preclinical validation, toxicology, and clinical trials before clinical applicability can be assessed.
This is a preclinical study combining transcriptomic analysis, virtual screening, and chemical synthesis followed by testing in animal models, raising mechanistic questions about AKR1B10 and COF scaffolds rather than establishing clinical efficacy.
As stated by the source record.
Quoted from the source exactly as published.
This work does not yet support clinical decision-making or patient treatment. It provides a foundation for drug discovery targeting AKR1B10 in ALD and highlights a novel COF-based delivery platform, but requires progression through preclinical validation, toxicology, and clinical trials before clinical applicability can be assessed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Alcoholic liver disease (ALD) incidence is rising globally, yet effective targeted therapies remain elusive. In recent years, bioactive molecules have gained prominence in liver disease research. However, no natural inhibitors targeting key drivers of ALD have yet to be reported. Herein, we first identified AKR1B10 as a key pathogenic driver through transcriptomic analysis of 33 ALD patients and 23 healthy controls. Through virtual screening, we discovered four inhibitors targeting this enzyme, including ellagic acid, vitamin B8, hematoxylin, and porphyrin. Inspired by these findings, we developed four bioactive molecule-derived covalent organic frameworks (COFs) by polymerizing these inhibitors with a spinach-derived tetraboryl-modified porphyrin. Following zinc coordination and hyaluronic acid (HA) modification, the resulting HA-grafted, zinc-coordinated COF composites exhibited significant therapeutic efficacy in acute alcohol-intoxicated mice. Notably, the ellagic acid-based COF system loaded with miRNA-223 ameliorated hepatocyte apoptosis, oxidative stress, lipid accumulation, and macrophage polarization in ALD mice. Furthermore, serum untargeted metabolomics confirmed its role in regulating bile acid metabolism and restoring metabolic homeostasis. This work not only presents the first bioactive molecule-derived COFs and expands the diversity of COF-based therapeutics but also offers a highly promising multifunctional nanoplatform for targeted ALD therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.